UNSPSC 51312314: Diphenhydramine tannate

This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C76H52O46.C17H21NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OPI52249ZG. European Medicines Agency schedules diphenhydramine tannate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01775MIG. Most nations, for tariff and trade purposes, schedule diphenhydramine tannate under HS 29221980 and SITC 51461.

SMILES: As of Q4 2014, DIPHENHYDRAMINE TANNATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51312314 Diphenhydramine tannate (Commodity) captures pharmaceutical products for state and local health and human services programs, though recent solicitations under this code show minimal direct activity specific to this active pharmaceutical ingredient alone. The code appears underutilized relative to the broader procurement landscape for generic pharmaceuticals and over-the-counter medications that state and local health agencies actually buy at scale. State and local buyers—including county health departments, state health and human services commissions, and cooperative purchasing alliances—procure pharmaceuticals through multi-product RFPs and cooperative agreements rather than ingredient-level solicitations, making this Commodity-tier code a less common pathway for individual drug formulations.

Recent state and local opportunities tagged to this code show limited direct relevance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with awarded vendors effective July 1, 2026. Seminole County, Florida released an IFB (due July 26, 2023) for Naloxone and Safe Drug Deactivation Systems—a community health procurement unrelated to diphenhydramine tannate formulations. The Texas Health and Human Services Commission posted an exploratory RFI (April 3, 2026) on direct-to-manufacturer prescription programs, signaling future formal solicitations. Activity clusters in Florida and Texas, with cooperative purchasing extending across the Midwest and Pacific Northwest. The code sees infrequent direct solicitation; pharmaceutical procurements at state and local scale typically aggregate multiple ingredients and formulations under broader family-level codes rather than targeting individual drug substances.